1. Happy Thanksgiving from Cafepharma! Our news staff will be off on Thursday, and will be feeding news on a limited basis throughout the holiday weekend. CP Today will return on Monday, November 30. We hope you enjoy this time, and stay safe! — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Zeposia will Flop. Fallout will affect many

Discussion in 'Bristol-Myers Squibb' started by anonymous, Jun 14, 2020 at 8:25 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The timing is fortune. Out of everyone’s control.

    but there is no real access and the providers have no time for switching or talking new therapies.
    Yes yes we know done have will the ones I’m out pocket but overall this launch will flop.
     

  2. anonymous

    anonymous Guest

    Overhead of personnel is costly supporting this launch.
     
  3. anonymous

    anonymous Guest

    Not going well at all
     
  4. anonymous

    anonymous Guest

    Product profile better than anticipated. Our problem has been personnel all along. We had a chance to put the right people in place to create a "sales" culture and we let Todd do his thing for too long. We passed on the right people in the name of those he knew. Things flow downhill from there. Then the merger. Some of the very best were precluded from coming with us because they were Otezla people. If we had their top 20% (who were all willing to come), we would be fine. Instead, we are surrounded by Jason and Todd types. When you combine that with the BMY culture of activity over performance, it gets rotten quick. I am hoping to hold on through COVID and then get out.
     
  5. anonymous

    anonymous Guest

    Let’s be real this product launch for MS has not been the blockbuster we all thought or told it would be
     
  6. anonymous

    anonymous Guest

    The reimbursement support flat out “SUCKS”

    that team is worthless
     
  7. anonymous

    anonymous Guest

    well patient services is all that is helping this launch by sending out free drug
     
  8. anonymous

    anonymous Guest

    Yea this won’t last into next year. There are HIGH salaries sitting in their hands. The entire reimbursement team does N O T H I N G

    Time sever.
     
  9. anonymous

    anonymous Guest

    It is a FLOP. Big FLOP
     
  10. anonymous

    anonymous Guest

    How long until a restructure?
     
  11. anonymous

    anonymous Guest

    Why does the uptake suck, I don’t get it. It’s “easier” to get onboard. Won’t look good when leadership sees Novartis is eating our lunch.
     
  12. anonymous

    anonymous Guest

    I am a competitor in the West Coast and I can say that nobody is writing this. Its so bad that I feel sorry for the rep. Zeposia is a decent drug but not able to find a niche.
     
  13. anonymous

    anonymous Guest

    Worth applying for? Sinking ship? What’s the reality out in the field?
     
  14. anonymous

    anonymous Guest

    So happy I declined to move over. I hear from others that transferred over from celebrity that they are posting for jobs weekly to get out.
     
  15. anonymous

    anonymous Guest

    From celgene
     
  16. anonymous

    anonymous Guest

    Meanwhile, Ofa is kicking ass!
     
  17. anonymous

    anonymous Guest

    I can definitely say that OFA is killing here in S. CA and I’m probably gonna need to be looking for a new gig soon. All of those east coaster/south/Midwest—are you seeing OFA taking off in your area?
     
  18. anonymous

    anonymous Guest

    Who’s going to lead this GI team if not celgene People
     
  19. anonymous

    anonymous Guest

    Well the heat is on! And this did not go as planned

    and cutting heads will happen.

    THIS WAS FORECASTED to be HUGE

    but it’s not even close.